Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Chan, S.L., Miksad, R., Cicin, I., Chen, Y., Klumpen, H.J., Kim, S., Lin, Z.Z., Youkstetter, J., Sen, S., Cheng, A.-L., El-Khoueiry, A.B., Meyer, T., Kelley, R.K., Abou-Alfa, G.K.Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz422.005
Date:
November, 2019
File:
PDF, 89 KB
2019